HIV-1 Drug Resistance Mutation Analyses of Cameroon-Derived Integrase Sequences

被引：0
|
作者：
Mikasi, Sello Given [1 ]
Isaacs, Darren [2 ]
Ikomey, George Mondinde [3 ]
Shimba, Henerico [1 ,4 ]
Cloete, Ruben [3 ]
Jacobs, Graeme Brendon [1 ]
机构：
[1] Stellenbosch Univ, Fac Med & Hlth Sci, Dept Pathol, Div Med Virol, ZA-7505 Cape Town, South Africa
[2] Univ Western Cape, South African Natl Bioinformat Inst, South African Med Res Council, Bioinformat Unit, Cape Town, South Africa
[3] Univ Yaounde I, Fac Med & Biomed Sci, Ctr Study & Control Communicable Dis, Yaounde, Cameroon
[4] Bugando Med Ctr, Mwanza, Tanzania
来源：
AIDS RESEARCH AND HUMAN RETROVIRUSES | 2021年 / 37卷 / 01期
基金：
英国医学研究理事会; 新加坡国家研究基金会;
关键词：
HIV-1; integrase; resistance; Cameroon; diversity; CRF02_AG; DOLUTEGRAVIR; RALTEGRAVIR;
D O I：
10.1089/aid.2020.0022
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
HIV-1 integrase (IN) is a primary target for combination antiretroviral therapy. Only a limited number of studies report on the emergence of resistance-associated mutations (RAMs) in Cameroon. We observed that 1.4% of sequence from treatment-naive patients had IN strand transfer inhibitor (INSTI) RAMs. These mutations confer resistance to raltegravir and elvitegravir. We also observed that 10.1% of the sequences have INSTI accessory RAMs. HIV-1 CRF02_AG was the predominant subtype (44.7%) in this study analyses. The occurrence of INSTI RAMs among the sequences at baseline needs to be monitored carefully.
引用
收藏
页码：54 / 56
页数：3
相关论文
共 50 条
  • [41] HIV-1 integrase genotyping is reliable and reproducible for routine clinical detection of integrase resistance mutations even in patients with low-level viraemia
    Armenia, D.
    Fabeni, L.
    Alteri, C.
    Di Pinto, D.
    Di Carlo, D.
    Bertoli, A.
    Gori, C.
    Carta, S.
    Fedele, V.
    Forbici, F.
    D'Arrigo, R.
    Svicher, V.
    Berno, G.
    Pizzi, D.
    Nicastri, E.
    Sarmati, L.
    Pinnetti, C.
    Ammassari, A.
    D'Offizi, G.
    Latini, A.
    Andreoni, M.
    Antinori, A.
    Ceccherini-Silberstein, F.
    Perno, C. F.
    Santoro, M. M.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2015, 70 (06) : 1865 - 1873
  • [42] Efficacies of Cabotegravir and Bictegravir against drug-resistant HIV-1 integrase mutants
    Steven J. Smith
    Xue Zhi Zhao
    Terrence R. Burke
    Stephen H. Hughes
    Retrovirology, 15
  • [43] HIV-1 integrase strand transfer inhibitors: a review of current drugs, recent advances and drug resistance
    Mbhele, Nokuzola
    Chimukangara, Benjamin
    Gordon, Michelle
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2021, 57 (05)
  • [44] HIV-1 Integrase Inhibitors That Are Broadly Effective against Drug-Resistant Mutants
    Smith, Steven J.
    Zhao, Xue Zhi
    Burke, Terrence R., Jr.
    Hughes, Stephen H.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2018, 62 (09)
  • [45] Efficacies of Cabotegravir and Bictegravir against drug-resistant HIV-1 integrase mutants
    Smith, Steven J.
    Zhao, Xue Zhi
    Burke, Terrence R., Jr.
    Hughes, Stephen H.
    RETROVIROLOGY, 2018, 15
  • [46] Drug Resistance Mutations Against Protease, Reverse Transcriptase and Integrase Inhibitors in People Living With HIV-1 Receiving Boosted Protease Inhibitors in South Africa
    Obasa, Adetayo Emmanuel
    Mikasi, Sello Given
    Brado, Dominik
    Cloete, Ruben
    Singh, Kamlendra
    Neogi, Ujjwal
    Jacobs, Graeme Brendon
    FRONTIERS IN MICROBIOLOGY, 2020, 11
  • [47] Phylogenetic and Drug-Resistance Analysis of HIV-1 Sequences From an Extensive Paediatric HIV-1 Outbreak in Larkana, Pakistan
    Abidi, Syed Hani
    Nduva, George Makau
    Siddiqui, Dilsha
    Rafaqat, Wardah
    Mahmood, Syed Faisal
    Siddiqui, Amna Rehana
    Nathwani, Apsara Ali
    Hotwani, Aneeta
    Shah, Sharaf Ali
    Memon, Sikander
    Sheikh, Saqib Ali
    Khan, Palwasha
    Esbjoernsson, Joakim
    Ferrand, Rashida Abbas
    Mir, Fatima
    FRONTIERS IN MICROBIOLOGY, 2021, 12
  • [48] HIV-1 Integrase Inhibitors with Modifications That Affect Their Potencies against Drug Resistant Integrase Mutants
    Smith, Steven J.
    Zhao, Xue Zhi
    Passos, Dario Oliveira
    Pye, Valerie E.
    Cherepanov, Peter
    Lyumkis, Dmitry
    Burke, Terrence R., Jr.
    Hughes, Stephen H.
    ACS INFECTIOUS DISEASES, 2021, 7 (06): : 1469 - 1482
  • [49] Elvitegravir: a once-daily, boosted, HIV-1 integrase inhibitor
    Lampiris, Harry W.
    EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2012, 10 (01) : 13 - 20
  • [50] HIV-1 Integrase T218I/S Polymorphisms Do Not Reduce HIV-1 Integrase Inhibitors' Phenotypic Susceptibility
    Rodriguez-Lopez, Elliott R.
    Lopez, Pablo
    Rodriguez, Yadira
    Sanchez, Raphael
    Acevedo, Van-Sergei
    Encarnacion, Jarline
    Tirado, Grissell
    Ortiz-Sanchez, Carmen
    Mesplede, Thibault
    Rivera-Amill, Vanessa
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2025, 41 (01) : 43 - 54
12345